Lupe Zermeno, CAADE Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 2034 Kwis Ave, Hacienda Heights, CA 91745 Phone: 626-400-9278 |
Kristen K Tachiki, LCSW Counselor Medicare: Medicare Enrolled Practice Location: 15014 Denley St, Hacienda Heights, CA 91745 Phone: 626-384-9756 |
Ms. Tomoko Bowling, LMFT, LPCC, CAMS-II Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 2211 S Hacienda Blvd Ste 203d, Hacienda Heights, CA 91745 Phone: 909-646-0739 |
Ms. Catherine Lee, LMFT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1504 Folkstone Ave, Hacienda Heights, CA 91745 Phone: 626-826-0619 |
Richard Anthony Carranza Ii Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 931 Galemont Ave, Hacienda Heights, CA 91745 Phone: 626-833-5634 |
News Archive
Planmeca, the world's largest privately owned dental imaging company and equipment manufacturer, announced today that it has made a non-controlling, strategic investment in E4D Technologies, LLC, developer of the E4D CAD/CAM Restorative System. This strategic investment reinforces Planmeca's on-going commitment to help dental providers improve patient care by offering a comprehensive portfolio of integrated digital dental solutions for dentists and dental laboratories.
Large numbers of people with severe rheumatoid arthritis are failing to take expensive medication as prescribed, according to a new multi-centre study led by researchers in Manchester.
A diet high in whole grain foods is associated with a significantly lower risk of developing cardiovascular disease, including heart disease and stroke, according to an analysis conducted by researchers at Wake Forest University School of Medicine.
New research finds that one out of 12 people who have a stroke will likely soon have another stroke, and one out of four will likely die within one year. Researchers say the findings highlight the vital need for better secondary stroke prevention. The study is published in the February 16, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
› Verified 4 days ago